MedTrace Logo

Atamparib in Patients With Advanced Solid Tumors

NCT07374419 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2026-01-28

No results posted yet for this study

Summary

This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).

Conditions

Interventions

DRUG

atamparib escalation levels

Bid, Oral, escalating at different dose levels

DRUG

atamparib RP2D

Bid, oral, RP2D

Sponsors & Collaborators

  • Nerviano Medical Sciences (Shanghai) Ltd.

    lead INDUSTRY

Principal Investigators

  • Caicun Zhou, Dr. · Shanghai East Hospital, Yuntailu 1800

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-10
Primary Completion
2028-07-31
Completion
2029-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07374419 on ClinicalTrials.gov